Loading clinical trials...
Loading clinical trials...
A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate the Efficacy and Safety of Ocrelizumab in Comparison to Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Conditions
Interventions
Interferon beta-1a
Ocrelizumab-matching placebo
+2 more
Locations
165
United States
Hope Research Institute
Phoenix, Arizona, United States
HonorHealth Neurology
Scottsdale, Arizona, United States
Territory Neurology and Research Institute
Tucson, Arizona, United States
Collaborative Neuroscience Research, LLC
Long Beach, California, United States
Stanford University Medical Center
Palo Alto, California, United States
University of Colorado
Denver, Colorado, United States
Start Date
September 20, 2011
Primary Completion Date
May 12, 2015
Completion Date
December 30, 2022
Last Updated
March 8, 2024
NCT05344469
NCT07426991
NCT06433752
NCT06617793
NCT04047628
NCT06486779
Lead Sponsor
Hoffmann-La Roche
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions